Lucid Diagnostics (LUCD) Net Cash Flow Growth (5y) (2025 - 2026)
Lucid Diagnostics (LUCD) Net Cash Flow Growth (5y) (2025 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.52 Bn | 176.22 Bn | 6.27 Bn |
| 2 | Stryker | 128.83 Bn | 125.95 Bn | 3.81 Bn |
| 3 | Medtronic | 108.61 Bn | 99.39 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.35 Bn | 66.90 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.53 Bn | 44.86 Bn | 1.29 Bn |
| 6 | Dexcom | 28.42 Bn | 27.30 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.34 Bn | 26.06 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.92 Bn | 26.35 Bn | - |
| 9 | Koninklijke Philips | 25.49 Bn | 22.36 Bn | 2.07 Bn |
| 10 | Lucid Diagnostics | 129.27 Mn | 101.39 Mn | -325,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -209.62% |
| Dec 31, 2025 | -178.44% |